About

Problem

Cancer is a major burden and associated costs are increasing rapidly. There is an urgent need for better treatments, and new therapies are approved at an encouraging rate. However, diagnostic tools for selecting which drugs are likely to be effective or not for individual patients are lacking. Hence, oncological therapy is characterized by ubiquitous under- and over-treatment. In fact, most patients who are treated with chemotherapy receive no clinical benefit, but still suffer from harmful side-effects. This is not only detrimental to patients, but also hugely wasteful to healthcare systems and society.

Solution

In vitro diagnostics based on clinical-grade drug screening has the potential to radically improve the therapeutic precision and efficacy in the treatment of most cancers. Crucially, it may pave the way for curative combination treatments in the future.

Company

Oncosyne is a biotechnology start-up. Our clinical-stage technology platform will be evaluated in a performance study anticipated to start in 2023. In brief, we cultivate the patient’s own living cancer cells and test them against an array of clinically relevant drugs and drug combinations. The product is a diagnostic report that identifies both which cancer drugs are likely to be efficacious and which are not. The test will be marketed as a therapeutic decision tool towards pharmaceutical industry, medical laboratories, and public and private hospitals.

Vision

Our vision is to provide game-changing functional diagnostic tools that give cancer patients significantly better and longer lives.

Careers

Job descriptions will be announced later. Please let us know if you're interested in joining an ambitious biotech start-up and bring game-changing cancer diagnostic to the clinic.